ThromboGenics has appointed Dr Staf Van Reet, currently on the ThromboGenics Board of Directors, as the company's new Chairman.
was previously Head of R&D at Janssen Pharmaceuticals, and was co-founder of Movetis N.V. and Chairman of its Board of Directors until
, when the company was acquired by Shire S.a.r.l. Currently, he is Chairman of the Board of Directors of Actogenix N.V. and Okapi Sciences N.V. and a director of Biocartis S.A., Therasolve N.V. and VIB (the Flemish Institute of Biotechnology).
Dr Staf Van Reet said
Desiré has made a huge contribution to the growth of ThromboGenics and the successful development of
. On behalf of the entire ThromboGenics team, I am extremely grateful for his dedication and commitment to the Company, which is now a leader in the European biotech industry. I look forward to continuing his record and to ensure the successful growth trajectory of
and further development of ThromboGenics
emerging portfolio of therapies for the treatment of diabetes-related retinal diseases.
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company's lead product, JETREA
(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in
ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA
the United States
. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon's net sales of JETREA
ThromboGenics and Alcon intend to share the costs equally of developing JETREA
for a number of new vitreoretinal indications.
is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. Alcon has launched JETREA
in the UK,
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications.